The Oncology Institute appoints Kim Tzoumakas to Board of Directors

Oncology Institute, Inc.

Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.
Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.
She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.
She was not initially assigned to any board committees; term expires at 2027 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.